| Document Date: 2014-10-15 16:53:45
Open Document File Size: 377,76 KBShare Result on Facebook
Company Pfizer / GlaxoSmithKline / HIV/AIDS / Shionogi / Immunodeficiency Syndrome / Healthcare ViiV Healthcare / Corporate Communications GlaxoSmithKline Inc. / / Country Canada / / Event M&A / / IndustryTerm treatment of HIV / / MedicalCondition HIV infection / HIV / disease / Acquired Immunodeficiency Syndrome / HIV infections / AIDS / infection / infections / / Organization NHS / Centers for Disease Control and Prevention / / Person Gregory Reinaud / / / Position General Manager / / Product abacavir / lamivudine / / URL http /
SocialTag |
For Immediate Release ViiV Healthcare receives approval for Triumeq™ (dolutegravir/abacavir/lamivudine), in Canada - a new once-daily single-pill regimen for the treatment of HIV Laval (October 14th, 2014) – ViiV He